Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Perifosine in Recurrent Malignant Gliomas
NCT02238496Phase 1Completed
- Sponsor
- Andrew B. Lassman
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of perifosine and temsirolimus in malignant glioma, glioblastoma (GBM), anaplastic astrocytoma (AA) and 2 more, sponsored by Andrew B. Lassman. Started Dec 2014; status: completed.
02
Drugs
perifosinetemsirolimus
03
Conditions
malignant gliomaglioblastoma (GBM)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)mixed glioma
Beyond the preview
Go deeper on NCT02238496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238496.